Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM.

J Exp Med. 2010 Sep 27;207(10):2175-86. doi: 10.1084/jem.20100637. Epub 2010 Sep 6.

2.

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD.

Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Epub 2011 Apr 5. Review.

3.

Vaccination for malignant melanoma: recent developments.

Jäger D, Jäger E, Knuth A.

Oncology. 2001;60(1):1-7. Review.

PMID:
11150901
4.

Revisiting immune exhaustion during HIV infection.

Khaitan A, Unutmaz D.

Curr HIV/AIDS Rep. 2011 Mar;8(1):4-11. doi: 10.1007/s11904-010-0066-0. Review.

5.

Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.

Ferris RL, Lu B, Kane LP.

J Immunol. 2014 Aug 15;193(4):1525-30. doi: 10.4049/jimmunol.1400557. Review.

6.

Emerging Tim-3 functions in antimicrobial and tumor immunity.

Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK.

Trends Immunol. 2011 Aug;32(8):345-9. doi: 10.1016/j.it.2011.05.003. Epub 2011 Jun 21. Review.

7.

Emerging immune checkpoints for cancer therapy.

Li X, Hu W, Zheng X, Zhang C, Du P, Zheng Z, Yang Y, Wu J, Ji M, Jiang J, Wu C.

Acta Oncol. 2015 Nov;54(10):1706-13. doi: 10.3109/0284186X.2015.1071918. Epub 2015 Sep 11. Review.

PMID:
26361073
8.

Tim-3 and its role in regulating anti-tumor immunity.

Das M, Zhu C, Kuchroo VK.

Immunol Rev. 2017 Mar;276(1):97-111. doi: 10.1111/imr.12520. Review.

9.

Regulation of T cell responses by the receptor molecule Tim-3.

Gorman JV, Colgan JD.

Immunol Res. 2014 Aug;59(1-3):56-65. doi: 10.1007/s12026-014-8524-1. Review.

10.

Role of Regulatory T Cells and Inhibitory Molecules in the Development of Immune Exhaustion During Human Immunodeficiency Virus Type 1 Infection.

Gonzalez SM, Zapata W, Rugeles MT.

Viral Immunol. 2016 Jan-Feb;29(1):2-10. doi: 10.1089/vim.2015.0066. Epub 2015 Nov 13. Review.

PMID:
26566019
11.

Tim-3 and Tim-4 as the potential targets for antitumor therapy.

Cheng L, Ruan Z.

Hum Vaccin Immunother. 2015;11(10):2458-62. doi: 10.1080/21645515.2015.1056953. Review.

12.

Transcriptional and epigenetic regulation of T cell hyporesponsiveness.

Pereira RM, Hogan PG, Rao A, Martinez GJ.

J Leukoc Biol. 2017 Jun 12. pii: jlb.2RI0317-097R. doi: 10.1189/jlb.2RI0317-097R. [Epub ahead of print] Review.

PMID:
28606939
13.

Role of TIM-3 in ovarian cancer.

Xu Y, Zhang H, Huang Y, Rui X, Zheng F.

Clin Transl Oncol. 2017 Mar 29. doi: 10.1007/s12094-017-1656-8. [Epub ahead of print] Review.

PMID:
28357631
14.

Resistance to immunotherapy: clouds in a bright sky.

Milano G.

Invest New Drugs. 2017 Apr 12. doi: 10.1007/s10637-017-0456-x. [Epub ahead of print] Review.

PMID:
28401366
15.

Molecular Dissection of CD8+ T-Cell Dysfunction.

Wang C, Singer M, Anderson AC.

Trends Immunol. 2017 Jun 26. pii: S1471-4906(17)30102-3. doi: 10.1016/j.it.2017.05.008. [Epub ahead of print] Review.

PMID:
28662970

Supplemental Content

Support Center